气溶胶苯妥英、吡非尼酮、曲前列尼尔和西地那非的实验。
Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.
机构信息
1 Department of Respiratory Diseases Shanghai Hospital, II Military University Hospital, Shanghai, China ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece ; 4 Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 5 II Medical Department, "Coburg" Regional Hospital, Coburg, Germany ; 6 Department of Interventional Pneumology, "Ruhrlandklinik", West German Lung Center, University Hospital, University Duisburg-Essen, Essen, Germany ; 7 Pulmonary Department, "Sotiria" Hospital of Chest Diseases, Athens, Greece.
出版信息
J Thorac Dis. 2014 Oct;6(10):1411-9. doi: 10.3978/j.issn.2072-1439.2014.08.38.
INTRODUCTION
Pulmonary hypertension (PH) has been identified either as a symptom or a primary entity. Several drugs are already on the market and other are being investigated. Idiopathic pulmonary fibrosis (IPF) is also a disease were several drugs are being investigated.
MATERIALS AND METHODS
Three jet nebulizers and three ultrasound nebulizers were used for our experiments with seven different residual cups and four different loadings. Bonsetan, treprostinil, sidenafil and pirfenidone were modified in order to be produced as aerosol in an effort to identify parameters which influence the droplet size production size.
RESULTS
The four-way ANOVA on droplet size using the jet nebulizers revealed two statistically significant factors, drug (F=6.326, P=0.0007) and residual cup (F=4.419, P=0.0007), and their interaction term (F=5.829, P<0.0001). Drugs bonsetan and pirfenidone produce equally the lowest mean droplet size (2.63 and 2.80 respectively) as compared to other two drug mean sizes. The ANOVA results, concerning the ultrasound nebulizers, revealed only the nebulizers as producing significant effect on droplet size (F=4.753, P=0.037).
DISCUSSION
Our study indicates the importance of the initial drug design formulation. Moreover, further investigation of the residual cup design is an additional parameter that can assist in the optimal droplet size production, indifferently of the drug formulation.
简介
肺动脉高压（PH）被确定为一种症状或主要实体。已经有几种药物在市场上，还有其他正在研究中。特发性肺纤维化（IPF）也是一种正在研究几种药物的疾病。
材料和方法
我们用三种射流喷雾器和三种超声喷雾器进行了实验，使用了七种不同的残留杯和四种不同的负载。Bonsetan、treprostinil、西地那非和吡非尼酮被修改为制成气雾剂，以确定影响液滴大小生产的参数。
结果
使用射流喷雾器的四因素方差分析显示出两个具有统计学意义的因素，药物（F=6.326，P=0.0007）和残留杯（F=4.419，P=0.0007），以及它们的交互项（F=5.829，P<0.0001）。药物 bonsetan 和 pirfenidone 产生的平均液滴尺寸最低（分别为 2.63 和 2.80），与其他两种药物的平均尺寸相比。超声喷雾器的方差分析结果仅显示喷雾器对液滴尺寸有显著影响（F=4.753，P=0.037）。
讨论
我们的研究表明初始药物设计配方的重要性。此外，对残留杯设计的进一步研究是一个额外的参数，可以帮助生产最佳的液滴尺寸，与药物配方无关。
Zotero 插件